Diagnostic and therapeutic strategies in the irritable bowel syndrome

Minerva Medica

Volumn 95, Issue 5, 2004, Pages 427-441

  Cremonini, F ^a   Talley, N J ^a,b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

Author keywords

Colonic disease, functional, diagnosis; Colonic disease, functional, physiopathology; Colonic disease, functional, therapy

Indexed keywords

ACETORPHAN; ALOSETRON; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIDEPRESSANT AGENT; ANTIENKEPHALINASE AGENT; CALPROTECTIN; CILANSETRON; CISAPRIDE; CLONIDINE; HERBACEOUS AGENT; LACTOFERRIN; LAXATIVE; LIDAMIDINE; LOPERAMIDE; MACROGOL; OCTREOTIDE; OPIATE; OPIATE ANTAGONIST; PIBOSEROD; PROBIOTIC AGENT; PRUCALOPRIDE; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN UPTAKE INHIBITOR; SOMATOSTATIN DERIVATIVE; SPASMOLYTIC AGENT; SULAMSEROD; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ANXIETY DISORDER; BEHAVIOR THERAPY; CELIAC DISEASE; CHINESE MEDICINE; COGNITIVE THERAPY; CONSTIPATION; DEPRESSION; DIAGNOSTIC TEST; DIARRHEA; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; ENTEROPATHY; FECES ANALYSIS; FIBER; FUNCTION TEST; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPNOSIS; INTESTINE FLORA; INTESTINE MOTILITY; INTESTINE TRANSIT TIME; IRRITABLE COLON; NUTRITIONAL INTOLERANCE; PELVIS FLOOR; PSYCHOTHERAPY; QT PROLONGATION; REVIEW; STOMACH EMPTYING;

ABDOMINAL PAIN; ADRENERGIC ALPHA-AGONISTS; ADULT; BEHAVIOR THERAPY; CATHARTICS; CROSS-OVER STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPNOSIS; IRRITABLE BOWEL SYNDROME; MALE; META-ANALYSIS; MIDDLE AGED; NARCOTICS; PARASYMPATHOLYTICS; PELVIC FLOOR; PHYTOTHERAPY; PLACEBOS; PSYCHOTHERAPY; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS; SENSITIVITY AND SPECIFICITY; SEROTONIN AGENTS;

EID: 8344242155     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-31.
2. Shih YC, Barghout VE, Sandler RS, Jhingran P, Sasane M, Cook S et al. Resource utilization associated with irritable bowel syndrome in the United States 1987-1997. Dig Dis Sci 2002;47:1705-15.
3. Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology 2003;124:1662-71.
4. Kim HJ, Camilleri M, Carlson PJ, Cremonini F, Ferber I, Stephens D et al. Association of distinct alpha-2 adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut 2004;53:829-37.
5. Levy RL, Jones KR, Whitehead WE, Feld SI, Talley NJ, Corey LA. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 2001;121:799-804.
6. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. BMJ 1978;2:653-4.
7. Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE. Rome II. The functional gastrointestinal disorders. Diagnosis, pathophysiology and treatment: a multinational consensus. McLean, VA: Degnon Associates; 2000.
8. Thompson WG, Dotevall DA, Drossman DA, Heaton KW, Kruis W. Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterol Int 1989;2:92-5.
9. Boyce PM, Koloski NA, Talley NJ. Irritable bowel syndrome according to varying diagnostic criteria: are the new Rome II criteria unnecessarily restrictive for research and practice? Am J Gastroenterol 2000;95:3176-83. Erratum in: Am J Gastroenterol 2001;96:1319.
10. Boyce PM, Koloski NA, Talley NJ. Irritable bowel syndrome according to varying diagnostic criteria: are the new Rome II criteria unnecessarily restrictive for research and practice? Am J Gastroenterol 2000;95:3176-83. Erratum in: Am J Gastroenterol 2001;96:1319.
11. Camilleri M. Management of the irritable bowel syndrome. Gastroenterology 2001;120:652-68.
12. Locke GR 3rd, Fett SL, Zinsmeister AR. Transition probabilities between functional gastrointestinal disorders in the community. Gastroenterology 2001;120:A52.
13. Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol 2002;97:2812-9.
14. Hamm LR, Sorrells SC, Harding JP, Northcutt AR, Heath AT, Kapke GF et al. Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria. Am J Gastroenterol 1999;94:1279-82.
15. Hammer J, Eslick GD, Howell SC, Altiparmak E, Talley NJ. Diagnostic yield of alarm features in irritable bowel syndrome and functional dyspepsia. Gut 2004;53:666-72.
16. Scrimshaw NS, Murray EB. The acceptability of milk and milk products in populations with a high prevalence of lactose intolerance. Am J Clin Nutr 1988;48 4 Suppl: 1079-159.
17. Parker TJ, Naylor SJ, Riordan AM, Hunter JO. Management of patients with food intolerance in irritable bowel syndrome: the development and use of an exclusion diet. J Hum Nutr Diet 1995;8:159-66.
18. Atkinson W, Gurney R, Sheldon TA, Whorwell PJ. Do food elimination diets improve irritable bowel syndrome? A double-blind trial based on IgG antibodies to food. Gastroenterology 2003;124:A29.
19. Sanders DS, Carter MJ, Hurlstone DP, Pearce A, Ward AM, McAlindon ME et al. Association of adult coeliac disease with irritable bowel syndrome: a case-control study in patients fulfilling ROME II criteria referred to secondary care. Lancet 2001;358:1504-8.
20. Wahnschaffe U, Ullrich R, Riecken EO, Schulzke JD. Celiac disease-like abnormalities in a subgroup of patients with irritable bowel syndrome. Gastroenterology 2001;121:1329-38.
21. Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002;123:450-60.
22. Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003;98:1309-14.
23. Williams AJ, Merrick MV, Eastwood MA. Idiopathic bile acid malabsorption: a review of clinical presentation, diagnosis, and response to treatment. Gut 1991;32:1004-6.
24. rd, Pemberton JH, Phillips SF. AGA technical review on constipation. American Gastroenterological Association. Gastroenterology 2000;119:1766-78.
25. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995;109:40-52. Erratum in: Gastroenterology 1997;113:1054.
26. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995;109:40-52. Erratum in: Gastroenterology 1997;113:1054.
27. Bouin M, Plourde V, Boivin M, Riberdy M, Lupien F, Laganiere M et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002;122:1771-7.
28. Olden KW. Diagnosis of irritable bowel syndrome. Gastroenterology 2002;122:1701-14.
29. Drossman DA, Creed FH, Olden KW, Svedlund J, Toner BB, Whitehead WE. Psychosocial aspects of the functional gastrointestinal disorders. Gut 1999;45 Suppl 2:1125-30.
30. Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Gastrointestinal tract symptoms and self-reported abuse: a population-based study. Gastroenterology 1994;107:1040-9.
31. Drossman DA, Talley NJ, Leserman J, Olden KW, Barreiro MA. Sexual and physical abuse and gastrointestinal illness. Review and recommendations. Ann Intern Med 1995;123:782-94.
32. Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann Intern Med 1995;122:107-12.
33. Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996;31:463-8.
34. Cann PA, Read NW, Holdsworth CD, Barends D. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984;29:239-47.
35. Lavo B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome: a double-blind placebo controlled study. Scand J Gastroenterol Suppl 1987;130:77-80.
36. Hovdenak N. Loperamide treatment of the irritable bowel syndrome. Scand J Gastroenterol Suppl 1987;130:81-4.
37. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000;133:136-47.
38. Dapoigny M, Abitbol JL, Fraitag B. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study. Dig Dis Sci 1995;40:2244-9.
39. Delvaux M, Louvel D, Lagier E, Scherrer B, Abitbol JL, Frexinos J. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 1999;116:38-45.
40. Camilleri M, Mayer EA, Drossman DA, Heath A, Dukes GE. McSorley D et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999;13:1149-59.
41. Jones RH, Holtmann G, Rodrigo L, Ehsanullah RS, Crompton PM, Jacques LA et al. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999;13:1419-27.
42. Bardhan KD, Bodemar G, Geldof H, Schutz E, Heath A, Mills JG et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000;14:23-34.
43. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000;355:1035-40.
44. Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001;161:1733-40.
45. Lembo T, Wright RA, Bagby B, Decker C, Gordon S, Jhingran P et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001;96:2662-70.
46. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003;15:79-86.
47. Houghton LA, Foster JM, Whorwell PJ. Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment Pharmacol Ther 2000;14:775-82.
48. Thumshirn M, Coulie B, Camilleri M, Zinsmeister AR, Burton DD, Van Dyke C. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2000;14:869-78.
49. Delvaux M, Louvel D, Mamet JP, Campos-Oriola R, Frexinos J. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998;12:849-55.
50. Mayer EA, Berman S, Derbyshire SW, Suyenobu B, Chang L, Fitzgerald L et al. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther 2002;16:1357-66.
51. Berman SM, Chang L, Suyenobu B, Derbyshire SW, Stains J, Fitzgerald L et al. Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron. Gastroenterology 2002;123:969-77.
52. Camilleri M, Atanasova E, Carlson PJ, Ahmad U, Kim HJ, Viramontes BE et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002;123:425-32.
53. Caras S. Cilansetron shows efficacy in male and female non-constipated patients with irritable bowel syndrome in a United States study. Gastroenterology 2001;120:A-217.
54. Ladabaum U, Brown MB, Pan W, Owyang C, Hasler WL. Effects of nutrients and serotonin 5-HT3 antagonism on symptoms evoked by distal gastric distension in humans. Am J Physiol Gastrointest Liver Physiol 2001;280:G201-8.
55. Talley NJ. Serotoninergic neuroenteric modulators. Lancet 2001;358:2061-8.
56. Camilleri M. Effects of somatostatin analogues on human gastrointestinal motility. Digestion 1996;57 Suppl 1:90-2.
57. Bradette M, Delvaux M, Staumont G, Fioramonti J, Bueno L, Frexinos J. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig Dis Sci 1994;39:1171-8.
58. Hasler WL, Soudah HC, Owyang C. Somatostatin analog inhibits afferent response to rectal distention in diarrhea-predominant irritable bowel patients. J Pharmacol Exp Ther 1994;268:1206-11.
59. Salazar-Lindo E, Santisteban-Ponce J, Chea-Woo E, Gutierrez M. Racecadotril in the treatment of acute watery diarrhea in children. N Engl J Med 2000;343:463-7.
60. Primi MP, Bueno L, Baumer P, Berard H, Lecomte JM. Racecadotril demonstrates intestinal antisecretory activity in vivo. Aliment Pharmacol Ther 1999;13 Suppl 6:3-7.
61. Malcolm A, Camilleri M, Kost L, Burton DD, Fett SL, Zinsmeister AR. Towards identifying optimal doses for alpha-2 adrenergic modulation of colonic and rectal motor and sensory function. Aliment Pharmacol Ther 2000;14:783-93.
62. Viramontes BE, Malcolm A, Camilleri M, Szarka LA, McKinzie S, Burton DD et al. Effects of an alpha(2)-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans. Am J Physiol Gastrointest Liver Physiol 2001;281:G1468-76.
63. Camilleri M, Kim DY, McKinzie S, Kim HJ, Thomforde G, Burton D et al. A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2003;1:111-21.
64. Prior A, Wilson KM, Whorwell PJ. Double-blind study of an alpha 2 agonist in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1988;2:535-9.
65. Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001;48:272-82.
66. Xing JH, Soffer EE. Adverse effects of laxatives. Dis Colon Rectum 2001;44:1201-9.
67. Smith B. Effect of irritant purgatives on the myenteric plexus in man and the mouse. Gut 1968;9:139-43.
68. nd. Severe idiopathic constipation is associated with a distinctive abnormality of the colonic myenteric plexus. Gastroenterology 1985;88(1 Pt 1):26-34.
69. Riemann JF, Schmidt H. Ultrastructural changes in the gut autonomic nervous system following laxative abuse and in other conditions. Scand J Gastroenterol Suppl 1982;71:111-24.
70. Noor N, Small PK, London MA, Hau C, Campbell FC. Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome. Scand J Gastroenterol 1998;33:605-11.
71. Farup PG, Hovdenak N, Wetterhus S, Lange OJ, Hovde O, Trondstad R. The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand J Gastroenterol 1998;33:128-31.
72. Schutze K, Brandstatter G, Dragosics B, Judmaier G, Hentschel E. Double-blind study of the effect of cis-apride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Aliment Pharmacol Ther 1997;11:387-94.
73. Van Outryve M, Milo R, Toussaint J, Van Eeghem P. "Prokinetic" treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J Clin Gastroenterol 1991;13:49-57.
74. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000;118:463-8.
75. Degen L, Matzinger D, Merz M, Appel-Dingemanse S, Osborne S, Luchinger S et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001;15:1745-51.
76. Coffin B, Farmachidi JP, Rueegg P, Bastie A, Bouhassira D. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003;17:577-85.
77. Muller-Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, Nault B et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15:1655-66.
78. Novick J, Miner P, Krause R, Glebas K, Bliesath H, Ligozio G et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002;16:1877-88.
79. Kellow J, Lee OY, Chang FY, Thongsawat S, Mazlam MZ, Yuen H et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003;52:671-6.
80. Talley NJ. Pharmacologic therapy for the irritable bowel syndrome. Am J Gastroenterol 2003;98:750-8.
81. Evans B, Clark W, Moore D, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2004;1:CD003960.
82. Morganroth J, Ruegg PC, Dunger-Baldauf C, Appel-Dingemanse S, Bliesath H, Lefkowitz M. Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am J Gastroenterol 2002;97:2321-7.
83. Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001;120:354-60.
84. Sloots CE, Poen AC, Kerstens R, Stevens M, De Pauw M, Van Oene JC et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther 2002;16:759-67.
85. Johanson JF, Miner PB, Parkman HI. Prucalopride improves bowel movement frequency and symptoms in patients with chronic constipation: results of two double-blind placebo-controlled trials. Gastroenterology 2000;118:A175.
86. Emmanuel AV, Roy AJ, Nicholls TJ, Kamm MA. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002;16:1347-56.
87. Camilleri M. Renzapride. Gastroenterology. In press 2004.
88. Hawkes ND, Rhodes J, Evans BK, Rhodes P, Hawthorne AB, Thomas GA. Naloxone treatment for irritable bowel syndrome: a randomized controlled trial with an oral formulation. Aliment Pharmacol Ther 2002;16:1649-54.
89. Taguchi A, Sharma N, Saleem RM, Sessler DI, Carpenter RL, Seyedsadr M et al. Selective postoperative inhibition of gastrointestinal opioid receptors. N Engl J Med 2001;345:935-40.
90. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001;15:355-61.
91. Kruis W, Weinzierl M, Schussler P, Holl J. Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome. Digestion 1986;34:196-201.
92. Secco GB, Di Somma C, Arnulfo G, Ricci C. Studio clinico controllato sulla azione del cloridrato di mebeverina nel trattamento del colon irritabile. Minerva Med 1983;74:699-702.
93. Tasman-Jones C. Mebeverine in patients with the irritable colon syndrome: double blind study. N Z Med J 1973;77:232-5.
94. Piai G, Visconti M, Imbimbo BP, Minieri R, Sollazzo M, Mazzacca G. Long term treatment of irritable bowel syndrome with cimetropium bromide, a new antimuscarinic coumpound. Curr Ther Res 1987;41:967-77.
95. Fielding JF. Double blind trial of trimebutine in the irritable bowel syndrome. Ir Med J 1980;73:377-9.
96. Moshal MG, Herron M. A clinical trial of trimebutine (Mebutin) in spastic colon. J Int Med Res 1979;7:231-4.
97. Baku F, Longanesi A, Blasi A, Monello S, Cestari R, Missale G et al. Clinical and functional evaluation of the efficacy of otilonium bromide: a multicenter study in Italy. Ital J Gastroenterol 1991;23 (8 Suppl 1):60-3.
98. Barbier P. Etude controllee en double aveugle d'un nouvel antispasmodique colique. Ars Med 1981;21:1879-80.
99. Battaglia G, Morselli-Labate AM, Camarri E, Francavilla A, De Marco F, Mastropaolo G et al. Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled. 15-week study. Aliment Pharmacol Ther 1998;12:1003-10.
100. Schafer VE, Ewe K. [The treatment of irritable colon. Efficacy and tolerance of buscopan plus, buscopan, paracetamol and placebo in ambulatory patients with irritable colon]. Fortschr Med 1990;108:488-92.
101. Delmont J. [The value of adding an antispasmodic musculotropic agent in the treatment of painful constipation in functional colopathies with bran. Double-blind study]. Med Chir Dig 1981;10:365-70.
102. Page JG, Dirnberger GM. Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). J Clin Gastroenterol 1981;3:153-6.
103. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000;108:65-72.
104. Heefner JD, Wilder RM, Wilson ID. Irritable colon and depression. Psychosomatics 1978;19:540-7.
105. Mertz H, Pass R, Kodner A, Yan-Go F, Fullerton S, Mayer EA. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998;93:160-5.
106. Myren J, Lovland B, Larssen SE, Larsen S. A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome. Scand J Gastroenterol 1984;19:835-43.
107. Rajagopalan M, Kurian G, John J. Symptom relief with amitriptyline in the irritable bowel syndrome. J Gastroenterol Hepatol 1998;13:738-41.
108. Tanum L, Malt UF. A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin. Scand J Gastroenterol 1996;31:318-25.
109. Tripathi BM, Misra NP, Gupta AK. Evaluation of tricyclic compound (trimipramine) vis-a-vis placebo in irritable bowel syndrome. (Double blind randomised study). J Assoc Phys India 1983;31:201-3.
110. Vij JG, Jiloha RG, Kumar N. Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients. Indian J Psychiatry 1991:243-6.
111. Drossman DA, Toner BB, Whitehead WE, Diamant NE, Dalton CB, Duncan S et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003;125:19-31.
112. Kuiken SD, Tytgat GNJ, Boeckxstaens GEE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003;1:219-28.
113. Broekaert D, Vos R, Gevers AM. A double-blind randomized placebo-controlled crossover trial of citalopram, a selective serotonin reuptake inhibitor, in irritable bowel syndrome. Gastroenterology 2001;120: A641.
114. Creed F, Fernandes L, Guthrie E, Palmer S, Ratcliffe J, Read N et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003;124:303-17.
115. Boyce PM, Talley NJ, Balaam B, Koloski NA, Truman G. A randomized controlled trial of cognitive behavior therapy, relaxation training, and routine clinical care for the irritable bowel syndrome. Am J Gastroenterol 2003;98:2209-18.
116. Heymann-Monnikes I, Arnold R, Florin I, Herda C, Melfsen S, Monnikes H. The combination of medical treatment plus multicomponent behavioral therapy is superior to medical treatment alone in the therapy of irritable bowel syndrome. Am J Gastroenterol 2000;93:981-94.
117. Guthrie E, Creed F, Dawson D, Tomenson B. A controlled trial of psychological treatment for the irritable bowel syndrome. Gastroenterology 1991;100:450-7.
118. Harvey RF, Hinton RA, Gunary RM, Barry RE. Individual and group hypnotherapy in treatment of refractory irritable bowel syndrome. Lancet 1989;1:424-5.
119. Calvert EL, Houghton LA, Cooper P, Morris J, Whorwell PJ. Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 2002;123:1778-85.
120. Bensoussan A, Talley NJ, Hing M, Menzies R, Guo A, Ngu M. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA 1998;280:1585-9.
121. Langmead L, Rampton DS. Review article: herbal treatment in gastrointestinal and liver disease: benefits and dangers. Aliment Pharmacol Ther 2001;15:1239-52.
122. Madisch A, Holtmann G, Plein K, Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 2004;19:271-80.
123. Liu JH, Chen GH, Yeh HZ, Huang CK, Poon SK. Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial. J Gastroenterol 1997;32:765-8.
124. Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroenterol 1998;93:1131-5.
125. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable boxvel syndrome. Eur J Gastroenterol Hepatol 2001;13:1143-7.
126. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 2000;32:294-301.
127. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231-8.
128. Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17:895-904.